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Abstract 
The mechanisms by which statins are beneficial are incompletely understood. While the 
lowering of low-density lipoprotein concentration is associated with regression of 
atherosclerosis, the observed benefit of statin therapy begins within months after its initiation, 
making regression an unlikely cause. Although LDL-C lowering is the main mechanism by 
which statin therapy reduces cardiovascular events, evidence suggests that at least some of the 
beneficial actions of statins may be mediated by their pleiotropic effects. Thus, statins may 
modulate the function of cardiovascular cells and key signalling proteins, including small G-
proteins, to ultimately exert their pleiotropic effects. Sphingosine-1-phosphate (S1P) is a 
naturally occurring bioactive lysophospholipid that regulates diverse physiological functions 
in a variety of different organ systems. Within the cardiovascular system, S1P mediates 
cardioprotection following ischemia/reperfusion injury, anti-inflammatory response, 
improvement of endothelial function, increased mobilization and differentiation of endothelial 
progenitor cells, inhibition of oxidation, and anti-atherogenic and anti-thrombotic actions. 
Early evidence suggests that the pleiotropic effects of statins may be related to an increase in 
S1P signalling. This review focuses on S1P signalling as the potential mechanism underlying 
the pleiotropic effects of statins. An improved understanding of this mechanism may be vital 
for establishing the clinical relevance of statins and their importance in the treatment and 
prevention of coronary artery disease. Key points Several studies have demonstrated a benefit 
from lowering serum LDL-C with statins in patients with and without clinical evidence of 
CAD. These may be mediated by the pleiotropic effects of statins-the mechanisms of which 
are incompletely understood. Early evidence suggests that statins may increase S1P signalling 
pathways through upregulation of the expression of S1P receptors and an increase in plasma 
levels of S1P to ultimately exert their pleiotropic effects. Future clinical trials and basic 
science research aimed at the underlying mechanisms of the pleiotropic effects of statins 
should enlighten us to their relative clinical relevance and importance. 
 
 
